Novo Nordisk A/S with ticker code (NVO) now have 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The range between the high target price and low target price is between 133.81 and 119.3 calculating the average target price we see 127.45. Now with the previous closing price of 104.83 this now indicates there is a potential upside of 21.6%. The 50 day MA is 109.21 while the 200 day moving average is 107.88. The market cap for the company is $244,377m. You can visit the company’s website by visiting: https://www.novonordisk.com
The potential market cap would be $297,109m based on the market concensus.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.